Previous 10 | Next 10 |
Gainers: IFRX +40.1% . CERS +9.9% . NVAX +8.3% . TWOU +4.7% . More news on: InflaRx N.V., Cerus Corporation, Novavax, Inc., Stocks on the move, , Read more ...
InflaRx N.V. (NASDAQ: IFRX ) announces that dosing is underway in a randomized clinical trial evaluating IFX-1 in patients with severe COVID-19-induced pneumonia. More news on: InflaRx N.V., Healthcare stocks news, Stocks on the move, Read more ...
InflaRx has dosed the first patient in an adaptive randomized controlled clinical study with IFX-1 in patients with severe COVID-19 pneumonia in the Netherlands InflaRx received initial positive human data from its licensee, Beijing Defengrei Biotechnology Co. Ltd. (BDB), suggesting a po...
These Top Penny Stocks Continue To Make New Highs The markets have been in a bit of turmoil over the past few days owing to the coronavirus scare. The virus has now spread beyond China and even places like Germany have confirmed cases, now. Due to the fear of economic slowdown, the stock ma...
SELLAS Life Sciences Group (NASDAQ: SLS ) +23% on positive follow-up phase 1/2 clinical data for Galinpepimut-S in acute myeloid leukemia. More news on: SELLAS Life Sciences Group, Inc., Alcon, Inc., Moderna, Inc., Stocks on the move, , Read more ...
Two out of the first five patients dosed with IFX-1 achieved complete remission Dose escalation warranted by pharmacodynamic analysis and approved by relevant authorities for a total enrollment of 18 patients in 3 dose cohorts InflaRx to present initial data at the SVB Leerink Global Hea...
JENA, Germany, Feb. 19, 2020 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, will present at the 9th Annual SVB Leerink Global Healthcare Conference February 25-27, 2020...
The following slide deck was published by InflaRx N.V. in conjunction with this Read more ...
JENA, Germany, Jan. 09, 2020 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, will present at the J.P. Morgan 38 th Annual Healthcare Conference being held January 13-16...
Gainers: ChemoCentryx (NASDAQ: CCXI ) +261% . More news on: ChemoCentryx, Inc., Akerna Corp., Proteostasis Therapeutics, Inc., Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
JENA, Germany, June 24, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced today that GOHIBIC (vilobelimab) has been selected by the Biomedical Advanced Research and Development ...
Thought leaders in complement inhibition, chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) provide compelling new insights into the strong development rationales, potential differentiation and medical role of INF904 in initially targeted indications and inflammation & imm...
JENA, Germany, May 21, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced data presented at the American Thoracic Society (ATS) 2024 International Conference that is being held f...